Clinical Trial Site Performance: Metrics, Benchmarks, and Improvement

Sponsors and CROs run internal performance reviews after every study closes. The clinical trial enrollment metrics they track determine which sites get offered future studies, and which do not. Most sites never see this data. This guide explains what is on that scorecard, what each metric actually signals at the site level, and what to do when any of them move in the wrong direction.

The Scorecard Sponsors Don't Share With You

After every study closes, most sponsors run a site performance review. The data lives in their clinical operations team, sometimes in a CRO's vendor management system, and occasionally in a formal preferred site program. Sites that perform well get invited back. Sites that underperform often stop receiving inquiries, with no explanation.

The metrics driving these decisions are not proprietary. They are standard across the industry. But they are rarely communicated back to sites in a way that allows for course correction. What follows is a breakdown of the seven metrics that appear on nearly every sponsor performance review, the benchmark range each one is measured against, and what each signals at the site level.

Sponsor and CRO reviews cluster these into four categories: enrollment, protocol deviations, query resolution, and data entry timeliness. Most sites track the first category closely and the last two barely at all, which is precisely why the last two are where a site can differentiate itself fastest.

A note on where evaluation starts: before a site is assessed on enrollment, it is assessed on fit. A thorough feasibility assessment before committing to a protocol is the earliest signal sponsors have about whether a site understands its own patient population.

Enrollment Rate: The Number Everyone Watches First

Enrollment rate measures how many patients a site randomizes per month against the target set at study activation. Sponsors calculate this at the site level, not just across the full study, which means underperformance at one site is visible even when the overall trial appears on track.

What constitutes a strong enrollment rate varies by phase and indication. A Phase 1 oncology trial with tight eligibility runs differently from a Phase 2 vaccine study with broad inclusion criteria. What stays consistent is how your site's rate compares to every other site on the same protocol.

The most common cause of a declining enrollment rate mid-study is not a patient availability problem. It is a pre-screening breakdown: patients who should have been disqualified early move too far through the process, consuming coordinator time without reaching randomization. If your enrollment rate is slower than projected and your screen fail rate is also elevated, that is where to look first.

For a detailed breakdown of the patterns that push sites below their targets, see why sites miss enrollment goals. 53% of clinical studies have experienced extended timelines, and one in six has taken more than twice as long as originally planned (Credevo). Enrollment rate is the leading indicator for which category a study falls into.

Screen Fail Rate: The Metric That Damages Reputations

Screen fail rate is the ratio of patients screened to patients randomized. If 20 patients are screened and 5 are randomized, the screen fail rate is 75%.

A high screen fail rate is one of the most visible signals that a site is not pre-screening effectively. Sponsors interpret it one of two ways: the site does not know its own patient population well enough to qualify candidates before screening begins, or the site's patient pool is not a genuine match for the protocol. Neither interpretation is useful for the site's standing.

Rates above 60–70% in non-rare disease trials tend to trigger sponsor review. What counts as normal varies enormously by indication, which is why a single site-wide number is close to useless. Genitourinary cancer trials have run 20 to 30% screen failure. Alzheimer's disease studies have run 70 to 80%, driven almost entirely by diagnostic criteria most patients cannot clear. The average across therapeutic areas sits near 36.3% (Applied Clinical Trials Online).

Track this segmented by protocol type, so a narrow-eligibility Phase 3 study gets compared against other narrow-eligibility Phase 3 studies rather than against a high-prevalence trial with a short exclusion list. A site that can say “our fail rate on comparably restrictive protocols runs X%” is in a far stronger position than one defending a single number in isolation.

The fix at most sites is simpler than it appears: a pre-screen checklist reviewed with the coordinator before each patient contact, and an honest audit of whether the site's patient database reflects the actual eligibility criteria. Sites that run detailed feasibility reviews before study activation enter studies with lower screen fail rates from the start. For the tactics that move this number without a protocol amendment, see reducing screen fail rates.

Time to First Patient: The Startup Signal Sponsors Remember

Time to first patient enrolled (also called First Patient In, or FPI) measures how long a site takes to go from initiation to randomizing the first participant. Sponsors track this because delayed startup shifts the entire trial timeline.

The benchmark: industry data puts the average time from site activation to first patient visit at around 30 days, with top-performing sites hitting 7 to 14 days through pre-built recruitment pipelines and just-in-time activation (Applied Clinical Trials Online, Clincove). Measured from contract execution instead, the industry average runs 3 to 6 months, while the fastest sites compress it to 45 days (Clincove). Site type matters too: community-based physician practices average 7.9 months from pre-study visit to first patient in, against 12.9 months for academic medical centers.

A site that activates quickly signals operational readiness. One that takes two or three months after initiation to enroll the first patient signals the opposite, regardless of how well enrollment performs later. Worse, that first number becomes the baseline a sponsor uses to forecast every future timeline the site commits to. Three factors account for most FPI delays at the site level.

Retention Rate and Protocol Deviation Frequency

Patient dropout and protocol deviations are both tracked at the site level. Neither affects enrollment numbers directly. Both affect whether the data a site generates is usable, and both inform sponsor decisions about future study allocation.

Retention rate measures what percentage of enrolled patients complete the study. High dropout rates signal a patient experience problem: visits are too burdensome, coordinator communication is inconsistent, or patients did not fully understand the time commitment at consent. Sites with chronic retention problems are less likely to receive long-duration protocols.

Protocol deviation frequency is a data quality signal. Frequent deviations (missed visits, incorrect dosing windows, improperly collected samples) suggest staff training gaps. One or two deviations over a long protocol are expected. A pattern of deviations at a single site is a flag in sponsor review.

Both are lagging indicators. By the time a pattern appears in sponsor reporting, the study is already affected. A site-side audit at the 25% enrollment mark, reviewing dropout reasons and deviation logs, gives enough lead time to intervene before the pattern becomes visible externally.

Query Resolution Time and Data Entry Timeliness: The Two Metrics Sites Forget

Enrollment rate and screen fail rate get a site's attention because they sit on the surface. Query resolution time and data entry timeliness get watched by data management and monitoring teams, quietly, and they carry real weight in how a site gets remembered. Almost no site tracks them internally, which makes them the fastest available differentiator.

Query resolution time measures how long a site takes to close a data query from creation to resolution. EDC queries average 9.6 days. Non-EDC queries run closer to 16.4 days. Industry benchmarks generally target an initial response within 3 to 5 business days, resolution of critical queries within 5 to 10 business days, and an on-time response rate of 90% or higher.

One practical note: track query age, not query count. A dashboard showing 12 open queries tells a site less than one showing the oldest open query is 18 days old. Age is the number a monitor reacts to.

Data entry timeliness, how quickly visit data reaches the EDC system after a patient visit, has no single published industry standard, but sponsors track it closely because a lag here delays every downstream milestone: database lock, interim analysis, safety reporting. A site that enters data within 48 to 72 hours of a visit as a standing rule builds a different reputation than one batching entry ahead of monitoring visits. Both metrics are entirely within site control, and neither requires a sponsor conversation to improve.

How Sponsors Use These Metrics to Allocate Future Studies

Performance data does not stay within one study. It follows a site across CRO relationships, across sponsors, and across years. A site that underperformed on enrollment rate for one protocol is unlikely to be the first call when the same sponsor's next study opens, even if a different CRO is managing the relationship.

Preferred site programs formalize this process. Sites that consistently meet enrollment targets, activate quickly, and deliver clean data get flagged in sponsor systems as high-performance sites. They receive earlier study inquiries, more favorable budget negotiations, and access to protocols with higher per-patient fees.

For sites without an existing sponsor relationship, performance in similar indications becomes the entry point. A strong enrollment feasibility report is often the first evidence a site presents that it is worth a formal site qualification visit. Sites with documented performance in comparable protocols have a clear advantage at that stage.

Building a Performance Dashboard for Your Site

Most sites do not track their own metrics in any structured way. Enrollment progress lives in a spreadsheet. Screen fail data surfaces when the sponsor requests a report. Retention numbers appear when a patient drops out and the coordinator updates the log.

A simple internal dashboard does not require a CTMS. Seven metrics, reviewed on a standing cadence by site leadership, provide enough visibility to catch problems before they reach sponsor review. The first five are monthly. The last two are worth a weekly glance, because both move fast enough that a month is too long to wait.

Regular review of these seven numbers, shared between site director and lead coordinator, gives your site the same visibility into its own performance that your sponsors already have. A site that tracks all seven for even one study cycle walks into its next feasibility conversation with a documented, protocol-specific performance record instead of a general impression.